Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AYTU vs CRON: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRON Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

CRON Overall Winner 6-Pillar Tally: AYTU 2 – 4 CRON Matrix Metrics: AYTU 3 – 7 CRON

As of Nov 16, 2026, Cronos Group Inc. Common Share (CRON) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas CRON carries 53.9/100 (HOLD) at $3.26 (13.3x Forward P/E, 6.1% operating margin).

  • Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile CRON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AYTU vs CRON
AYTU NASDAQ
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00
CRON NASDAQ Head-to-Head Winner
Cronos Group Inc. Common Share
Medicinal Chemicals & Botanical Products
$3.26
-3.48% 1D
Market Cap $1.2B
TTM Revenue $206M
Forward P/E 13.3x
Beta / 30D Vol 0.35β · 40% Vol
Unified Composite Score
53.9 / 100 HOLD
Tech 46.0 Fund 51.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 43.9 · SMA20: $3.41 · SMA50: $3.32

6-Pillar Scorecard Institutional Category Breakdown (AYTU 2 – 4 CRON)

Columns: Metric · AYTU · CRON
1. Valuation Multiples AYTU
Forward P/E 9.2x 13.3x
Trailing P/E 9.2x 21.3x
PEG Ratio N/M N/M
EV / Revenue 0.3x 4.1x
2. Growth & Scale CRON
Revenue Growth (YoY) +6.4% +74.6%
Earnings Growth (YoY) +0.0% -44.7%
TTM Revenue (USD) $58M $206M
Market Cap $19.6M $1.2B
3. Profitability & Quality CRON
Gross Margin 64.0% 46.3%
Operating Margin -14.4% 6.1%
Net Profit Margin -24.8% 28.0%
Return on Equity (ROE) -52.5% 6.1%
4. Balance Sheet & Cash Flow CRON
Cash Generation (TTM) -$1.4M $65M
Cash Flow Margin -2.4% 31.6%
Net Cash / Leverage $4.9M Net Cash $410M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRON
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 45.9% (20th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity 78.4% of Rev ($45M) 40.2% of Rev ($83M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AYTU (3) vs CRON (7)
Institutional Metric AYTU CRON Criterion Row Edge
Market Capitalization
Scale
$19.6M $1.2B Larger Scale CRON
Trailing P/E Ratio
Valuation
9.2x 21.3x Lower Multiple AYTU
Forward P/E Ratio
Valuation
9.2x 13.3x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+6.4% +74.6% Higher Growth CRON
Operating Margin (TTM)
Profitability
-14.4% 6.1% Higher Margin CRON
Net Profit Margin
Profitability
-24.8% 28.0% Higher Margin CRON
Return on Equity (ROE)
Capital Efficiency
-52.5% 6.1% Higher ROE CRON
52-Week Range Position
Momentum
5% ($2–$3) 60% ($2–$4) Stronger Trend CRON
Beta / 30D Volatility
Risk Regime
0.65β · 35% Vol 0.35β · 40% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 53.9 / 100 (HOLD) Higher Composite CRON
Trailing 12M Revenue (USD)
Operating Scale
$58M $206M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.0% 46.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · 4.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.4M ($4.9M Net Cash) $65M ($410M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRON +12.9 pp
AYTU: -11.27% · CRON: +1.63%
3M Horizon CRON +24.94 pp
AYTU: -23.31% · CRON: +1.63%
6M Horizon CRON +38.33 pp
AYTU: -13.81% · CRON: +24.52%
1Y Horizon CRON +43.69 pp
AYTU: -12.14% · CRON: +31.55%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AYTU Revenue CRON Revenue AYTU Op. Margin CRON Op. Margin Margin Leader
FY2019 $10M $20M -230.1% -645.5% AYTU
FY2020 $30M $50M -76.5% -469.6% AYTU
FY2021 $70M $60M -89.7% -452.2% AYTU
FY2022 $100M $90M -113.7% -128.4% AYTU
FY2023 $110M $90M -15.9% -97.2% AYTU
FY2024 $70M $120M -2.4% -65.1% AYTU
FY2025 $70M $150M -11.8% -11.9% AYTU
FY2026 $60M N/A -14.4% N/A AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRON CONSOLIDATION
57d in phase · OBV NEUTRAL
Current IV 45.9%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CRON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published
CRON Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.2B market capitalization and 6.1% operating margin.
OpEx & R&D Reinvestment 40.2% of Rev ($83M)
90D Engineering Disclosures 0 Published

Investor FAQ AYTU vs CRON Key Questions & Quantitative Answers

As of Nov 16, 2026, Cronos Group Inc. Common Share (CRON) is the stronger overall head-to-head candidate over AYTU BioPharma, Inc. (AYTU) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AYTU carries a Unified Composite Score of 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin), whereas CRON carries 53.9/100 (HOLD) at $3.26 (13.3x Forward P/E, 6.1% operating margin). Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile CRON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 43.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRON leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with CRON at +74.6% YoY revenue growth and -44.7% YoY earnings growth on $206M TTM revenue (46.3% gross margin, 6.1% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AYTU cumulative revenue shifted +500.0% while CRON shifted +650.0%. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus 40.2% of Rev ($83M) (0 disclosures) for CRON.

AYTU screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas CRON trades at 13.3x Forward P/E, 21.3x Trailing P/E, N/M PEG, and 4.1x EV/Revenue (31.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus CRON (6.1% ROE) capital efficiency.

In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, CRON carries 45.9% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.35β · 40% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.